GHRP-6
Growth Hormone Releasing Peptide-6
GHRP-6 remains popular in older bodybuilding circles, but pharmacies still face the same regulatory headwinds as with GHRP-2.
Current status
Restricted
Growth-hormone-related interest, with current federal compounding constraints still in play.
FDA category
Category 3
Can pharmacies compound this?
No
Reclassification expected?
Yes
Future policy changes could affect the whole family rather than GHRP-6 alone.
Primary Use
Growth-hormone-related interest
Regulatory Timeline
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Sep 27, 2024
Current status signal recorded: FDA currently places it in Category 3 rather than active evaluation..
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Get notified...
Get notified when GHRP-6 status changes
State-specific notes
Texas
Closely tied to federal restriction signals.